

In the format provided by the authors and unedited.

# IFN- $\gamma$ -independent immune markers of *Mycobacterium tuberculosis* exposure

Lenette L. Lu<sup>1,2</sup>, Malisa T. Smith<sup>3</sup>, Krystle K. Q. Yu<sup>3</sup>, Corinne Luedemann<sup>2</sup>, Todd J. Suscovich<sup>1,2</sup>, Patricia S. Grace<sup>2</sup>, Adam Cain<sup>2</sup>, Wen Han Yu<sup>1,2,4</sup>, Tanya R. McKittrick<sup>5</sup>, Douglas Lauffenburger<sup>4</sup>, Richard D. Cummings<sup>5</sup>, Harriet Mayanja-Kizza<sup>6</sup>, Thomas R. Hawn<sup>3</sup>, W. Henry Boom<sup>7</sup>, Catherine M. Stein<sup>7,8</sup>, Sarah M. Fortune<sup>1,2</sup>, Chetan Seshadri<sup>3,9\*</sup> and Galit Alter<sup>1,2,9\*</sup>

<sup>1</sup>Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA. <sup>2</sup>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. <sup>3</sup>Department of Medicine, University of Washington, Seattle, WA, USA. <sup>4</sup>Department of Biological Engineering, MIT, Cambridge, MA, USA. <sup>5</sup>Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. <sup>6</sup>Department of Medicine, Makerere University, Kampala, Uganda. <sup>7</sup>Department of Medicine, Case Western Reserve University and Univ. Hospitals Cleveland Medical Center, Cleveland, OH, USA. <sup>8</sup>Department of Population & Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA. <sup>9</sup>These authors contributed equally: Chetan Seshadri, Galit Alter. \*e-mail: [seshadri@u.washington.edu](mailto:seshadri@u.washington.edu); [galter@mgh.harvard.edu](mailto:galter@mgh.harvard.edu)

Supplementary Table 1: Demographic characteristics of study group.

Risk score is determined as previously described<sup>16</sup>. Means and medians are presented as indicated. Categorical variables were compared using a chi-square test, and continuous variables were compared using a Mann-Whitney test; p-values indicate significance according to these statistics. BCG scar indicates prior vaccination with Bacillus Calmette–Guérin (BCG).

	<b>“resister” TST-/IGRA-</b>	<b>LTBI TST+/IGRA+</b>	<b>p-value</b>
<b>Current age (median)</b>	20.00	22.50	0.371
<b>Age at recruitment (median)</b>	13	13.5	0.502
<b>Sex (% Female)</b>	42.9%	43.5%	0.951
<b>% with BCG scar</b>	61.2%	65.2%	0.830
<b>Pediatric risk score (mean)</b>	6.07	6.35	0.113
<b>Adult risk score (mean)</b>	6.26	6.70	0.296
<b>Duration of follow-up in years (median)</b>	9.31	8.47	0.780
<b>BMI (median)</b>	20.92	21.83	0.388

Supplementary Table 2: Demographics of subjects included in this study compared to those from the larger “resister” cohort.

Risk score is determined as previously described<sup>16</sup>. Means and medians are presented as indicated. Categorical variables were compared using a chi-square test, and continuous variables were compared using a Mann-Whitney test; p-values indicate significance according to these statistics. BCG scar indicates Bacillus Calmette–Guérin prior vaccination.

	<b>Subjects in this study</b>	<b>Subjects not included in this study</b>	<b>p-value</b>
<b>Current age (median)</b>	21.00	22.00	0.762
<b>Sex (% Female)</b>	43.2%	50.8%	0.226
<b>% with BCG scar</b>	63.2%	69.1%	0.972
<b>Pediatric risk score (mean)</b>	6.20	6.15	0.998
<b>Adult risk score (mean)</b>	6.49	6.45	0.718
<b>Duration of follow-up in years (median)</b>	9.16	9.99	0.024

Supplementary Table 3: Incidence of new TB cases

Person-years of follow-up were calculated based on last visit and subsequent follow-up dates. Number of new TB cases are shown along with the calculated incidence rate and 95% confidence intervals (CI).

	<b>PTST- TST-/IGRA-</b>	<b>LTBI TST+/IGRA+</b>
<b>Total cases</b>	144	303
<b>Person-years of follow-up</b>	1020	2212
<b>Cases of active TB</b>	2	4
<b>Incidence rate [95% CI]</b>	0.00196 [0-0.0047]	0.00180 [0.000036-0.00357]

Supplementary Table 4: Multi-parameter flow cytometry panel. The results reported in Figures 3 and 4 of this manuscript utilized an 11-color flow cytometry panel to analyze T cells following in vitro stimulation. Details regarding the antibodies used for these experiments are provided here.

<b>Specificity</b>	<b>Fluorophore</b>	<b>Clone</b>	<b>Catalog Number</b>	<b>Lot Number</b>	<b>Supplier</b>
<b>TNF</b>	FITC	MAb11	554512	6245784	BD Biosciences
<b>CD8a</b>	PerCP Cy5.5	SK1	341051	6012504	BD Biosciences
<b>IL-2</b>	PE	MQ1-17H12	559334	3263570	BD Biosciences
<b>CD3</b>	ECD	UCHT1	IM2705U	100	Beckman Coulter
<b>CD40L</b>	PE Cy5	TRAP1	555701	6119902	BD Biosciences
<b>CD107a</b>	PE Cy7	H4A3	561348	6084604	BD Biosciences
<b>IL-4</b>	APC	MP4-25D2	554486	5234935	BD Biosciences
<b>IL-17a</b>	Ax700	BL168	512318	B218394	BioLegend
<b>CD4</b>	APC Ax750	13B8.2	A94685	36	Beckman Coulter
<b>IFN-<math>\gamma</math></b>	V450	B27	560371	6105971	BD Biosciences
<b>Dead Cell Stain</b>	AmCyan		L34957	1878891	Life Technologies